Cakmakkaya Ozlem S, Kolodzie Kerstin, Apfel Christian C, Pace Nathan Leon
Department of Medical Education, University of Istanbul, Cerrahpasa Medical School, Istanbul, Turkey, 34500.
Cochrane Database Syst Rev. 2014 Nov 7;2014(11):CD008877. doi: 10.1002/14651858.CD008877.pub2.
Surgery remains a mainstay of treatment for malignant tumours; however, surgical manipulation leads to a significant systemic release of tumour cells. Whether these cells lead to metastases is largely dependent on the balance between aggressiveness of the tumour cells and resilience of the body. Surgical stress per se, anaesthetic agents and administration of opioid analgesics perioperatively can compromise immune function and might shift the balance towards progression of minimal residual disease. Regional anaesthesia techniques provide perioperative pain relief; they therefore reduce the quantity of systemic opioids and of anaesthetic agents used. Additionally, regional anaesthesia techniques are known to prevent or attenuate the surgical stress response. In recent years, the potential benefit of regional anaesthesia techniques for tumour recurrence has received major attention and has been discussed many times in the literature. In preparing this review, we aimed to summarize the current evidence systematically and comprehensively.
To establish whether anaesthetic technique (general anaesthesia versus regional anaesthesia or a combination of the two techniques) influences the long-term prognosis for individuals with malignant tumours.
We searched The Cochrane Library (2013, Issue 12), PubMed (1950 to 15 December 2013), EMBASE (1974 to 15 December 2013), BIOSIS (1926 to 15 December 2013) and Web of Science (1965 to 15 December 2013). We handsearched relevant websites and conference proceedings and reference lists of cited articles. We applied no language restrictions.
We included all randomized controlled trials or controlled clinical trials that investigated the effects of general versus regional anaesthesia on the risk of malignant tumour recurrence in patients undergoing resection of primary malignant tumours. Comparisons of interventions consisted of (1) general anaesthesia alone versus general anaesthesia combined with one or more regional anaesthetic techniques; (2) general anaesthesia combined with one or more regional anaesthetic techniques versus one or more regional anaesthetic techniques; and (3) general anaesthesia alone versus one or more regional anaesthetic techniques. Primary outcomes included (1) overall survival, (2) progression-free survival and (3) time to tumour progression.
Two review authors independently scanned the titles and abstracts of identified reports and extracted study data.All primary outcome variables are time-to-event data. If the individual trial report provided summary statistics with odds ratios, relative risks or Kaplan-Meier curves, extracted data enabled us to calculate the hazard ratio using the hazard ratio calculating spreadsheet. To assess risk of bias, we used the standard methodological procedures expected by The Cochrane Collaboration.
We included four studies with a total of 746 participants. All studies included adult patients undergoing surgery for primary tumour resection. Two studies enrolled male and female participants undergoing major abdominal surgery for cancer. One study enrolled male participants undergoing surgery for prostate cancer, and one study male participants undergoing surgery for colon cancer. Follow-up time ranged from nine to 17 years. All four studies compared general anaesthesia alone versus general anaesthesia combined with epidural anaesthesia and analgesia. All four studies are secondary data analyses of previously conducted prospective randomized controlled trials.Of the four included studies, only three contributed to the outcome of overall survival, and two each to the outcomes of progression-free survival and time to tumour progression. In our meta-analysis, we could not find an advantage for either study group for the outcomes of overall survival (hazard ratio (HR) 1.03, 95% confidence interval (CI) 0.86 to 1.24) and progression-free survival (HR 0.88, 95% CI 0.56 to 1.38). For progression-free survival, the level of inconsistency was high. Pooled data for time to tumour progression showed a slightly favourable outcome for the control group (general anaesthesia alone) compared with the intervention group (epidural and general anaesthesia) (HR 1.50, 95% CI 1.00 to 2.25).Quality of evidence was graded low for overall survival and very low for progression-free survival and time to tumour progression. The outcome of overall survival was downgraded for serious imprecision and serious indirectness. The outcomes of progression-free survival and time to tumour progression were also downgraded for serious inconsistency and serious risk of bias, respectively.Reporting of adverse events was sparse, and data could not be analysed.
AUTHORS' CONCLUSIONS: Currently, evidence for the benefit of regional anaesthesia techniques on tumour recurrence is inadequate. An encouraging number of prospective randomized controlled trials are ongoing, and it is hoped that their results, when reported, will add evidence for this topic in the near future.
手术仍然是恶性肿瘤治疗的主要手段;然而,手术操作会导致肿瘤细胞大量释放进入全身循环。这些细胞是否会导致转移很大程度上取决于肿瘤细胞的侵袭性与机体抵抗力之间的平衡。手术应激本身、麻醉药物以及围手术期阿片类镇痛药的使用会损害免疫功能,可能会使平衡朝着微小残留病灶进展的方向偏移。区域麻醉技术可提供围手术期疼痛缓解;因此,它们减少了全身使用的阿片类药物和麻醉药物的用量。此外,已知区域麻醉技术可预防或减轻手术应激反应。近年来,区域麻醉技术对肿瘤复发的潜在益处受到了广泛关注,并且在文献中已经讨论过多次。在撰写本综述时,我们旨在系统、全面地总结当前证据。
确定麻醉技术(全身麻醉与区域麻醉或两种技术联合使用)是否会影响恶性肿瘤患者的长期预后。
我们检索了考克兰图书馆(2013年第12期)、PubMed(1950年至2013年12月15日)、EMBASE(1974年至2013年12月15日)、BIOSIS(1926年至2013年12月15日)以及科学引文索引(1965年至2013年12月15日)。我们手工检索了相关网站、会议论文集以及被引用文章的参考文献列表。我们未设置语言限制。
我们纳入了所有调查全身麻醉与区域麻醉对原发性恶性肿瘤切除患者恶性肿瘤复发风险影响的随机对照试验或对照临床试验。干预措施的比较包括:(1)单纯全身麻醉与全身麻醉联合一种或多种区域麻醉技术;(2)全身麻醉联合一种或多种区域麻醉技术与一种或多种区域麻醉技术;以及(3)单纯全身麻醉与一种或多种区域麻醉技术。主要结局包括:(1)总生存期,(2)无进展生存期,以及(3)肿瘤进展时间。
两名综述作者独立筛选已识别报告的标题和摘要,并提取研究数据。所有主要结局变量均为事件发生时间数据。如果单个试验报告提供了带有比值比、相对风险或Kaplan-Meier曲线的汇总统计数据,提取的数据使我们能够使用风险比计算电子表格来计算风险比。为了评估偏倚风险,我们采用了考克兰协作网期望的标准方法程序。
我们纳入了四项研究,共746名参与者。所有研究均纳入了接受原发性肿瘤切除手术的成年患者。两项研究纳入了接受癌症大腹部手术的男性和女性参与者。一项研究纳入了接受前列腺癌手术的男性参与者,另一项研究纳入了接受结肠癌手术的男性参与者。随访时间为9至17年。所有四项研究均比较了单纯全身麻醉与全身麻醉联合硬膜外麻醉和镇痛。所有四项研究均为对先前进行的前瞻性随机对照试验的二次数据分析。在纳入的四项研究中,只有三项对总生存期结局有贡献,两项对无进展生存期和肿瘤进展时间结局有贡献。在我们的荟萃分析中,我们未发现任何一个研究组在总生存期(风险比(HR)1.03,95%置信区间(CI)0.86至1.24)和无进展生存期(HR 0.88,95% CI 0.56至1.38)结局方面具有优势。对于无进展生存期,不一致程度较高。汇总的肿瘤进展时间数据显示,与干预组(硬膜外麻醉和全身麻醉)相比,对照组(单纯全身麻醉)的结局略好(HR 1.50,95% CI 1.00至2.25)。总生存期的证据质量等级为低,无进展生存期和肿瘤进展时间的证据质量等级为极低。总生存期结局因严重不精确性和严重间接性而被降级。无进展生存期和肿瘤进展时间结局分别因严重不一致性和严重偏倚风险而被降级。不良事件的报告很少,无法进行数据分析。
目前,关于区域麻醉技术对肿瘤复发有益的证据不足。目前正在进行一些令人鼓舞的前瞻性随机对照试验,希望它们的结果在报告后将在不久的将来为该主题增添证据。